Yissum - Research Development Company of the Hebrew University

Mutant Human Embryonic Stem Cells

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

Mutant Human Embryonic Stem Cells
Project ID : 34-2011-2687

Description of the technology

Human embryonic stem cell lines derived from Pre-Implantation Genetic Diagnosis (PGD) embryos

Categories

Mutant Human Embryonic Stem Cells , drug screening, genetic disorders

Stem Cell Research Laboratory, Medical Genetics Institute, Shaare Zedek Medical Center

Objective

  • The Stem Cell Research Laboratory is a part of the Medical Genetics Institute in SZMC, which is the largest PGD performing center in the country and one of the leading PGD centers worldwide. The laboratory provides mutant HESC lines. Additionally, the lab investigates basic biological questions related to specific genetic disorders using mutant human embryonic stem cell lines as a model system.

Potential Applications

  • Drug screening- HESCs can potentially differentiate into all cell types in large numbers, so that the targeted tissues will be accessible for large-scale screening

  • Toxicology assessments of new drug candidates

  • Development of new therapeutic protocols, including gene therapy-based treatments

  • Improving the currently available treatments by identifying new drug targets

  • Invaluable resource to explore unresolved questions related to the biology of particular disorders in human.

Unique capabilities

  • Specialised staff

  • Appropriate equipment, for growing human embryos in culture and for the derivation and propagation of human embryonic stem cell lines from 5-7 day old IVF derived human embryos.

Advantages

  • A unique access to early stage genetically diseased human embryos

  • A board collection of genetically inherited diseases with a wide range of naturally inherited mutations.

  • An unlimited cell source for impaired cells in culture

  • Favourable over currently available human-based cellular models: do not require establishing cultures from biopsies of patients, unrestricted life span, can differentiate into all cell types

Research Interests

  • Understanding the pathology of particularly large trinucleotide repeat expansions, namely fragile X syndrome (FRAXA) and Myotonic Dystrophy type 1 (DM1)

  • The mechanisms by which HESCs regulate telomere length

Available Resources

  • Potential to derive HESC lines from healthy surplus IVF embryos (IRB 17/11)

  • Potential to obtain somatic cells from patients for the establishment of disease specific induced pluripotent stem (iPS) cells (initial stages of approval by SZMC's ethic committee).

Laboratory Contact

Rachel Eiges, PhD: Head of the Stem Cell Research Laboratory, Shaare Zedek Medical Center.

rachela@szmc.org.il

, tel: +972-26666721, fax: +972-26666935

Project manager

Shoshana Keynan
VP, Head of Business Development, Healthcare

Project researchers

Rachel Eiges
Shaare Zedek Medical Center,

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Clean Industrial Technologies
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Clinical Medicine
  • Anatomy, Pathology, Immunology, Physiology
  • Agro and Marine biotech
  • Other Medical/Health Related
  • Therapeutic
  • Diagnostic
  • Other (uncategorised)
  • Life Science & Biotechnology
  • Stem Cells

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.